StreetInsider.com News Articles

Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone

Mon, 27 Jul 2026 08:06:37 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) has filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone intended to support multiple therapeutic approaches for solid tumors, the company announced based on a press release statement.

The filing is designed to protect a platform that Aptevo says could be adapted into several cancer treatment formats, including radiopharmaceuticals, T-cell engagers, and other immune-based therapies, using the company's existing ADAPTIR and ADAPTIR-FLEX platforms.

Nectin-4 is present on several solid tumors, while PD-L1 can be found on both tumor cells and immune-suppressing cells within the tumor environment. Aptevo states the dual-targeting approach is intended to direct

Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone

Mon, 27 Jul 2026 08:06:37 -0400

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Mon, 27 Jul 2026 08:05:00 -0400

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach

SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo's oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation.

For Aptevo, the filing helps

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Mon, 27 Jul 2026 08:05:00 -0400

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach

For Aptevo, the filing helps

Form S-8 Aptevo Therapeutics Inc.

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813562.html

Form S-8 Aptevo Therapeutics Inc.

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813562.html

Form 8-K Aptevo Therapeutics Inc. For: Jun 29

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713538.html

Form 8-K Aptevo Therapeutics Inc. For: Jun 29

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713538.html

Aptevo gets $1.5M grant to advance APVO451 cancer therapy

Tue, 30 Jun 2026 08:06:22 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) has received a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support development of APVO451, a trispecific antibody-like immunotherapy candidate targeting solid tumors, according to a company statement.

The grant, awarded under the CARE Fund's Implementation and Outcomes Research program, will fund investigational new drug (IND)-enabling activities for APVO451, including preclinical studies. The CARE Fund supports cancer research conducted by public and private entities in Washington State.

APVO451 is designed to simultaneously target nectin-4, a tumor-associated marker expressed in multiple solid tumors, while activating CD40 on antigen-presenting cells and engaging

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Tue, 30 Jun 2026 08:05:00 -0400

SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced it has been awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund under its Implementation and Outcomes Research program to support investigational new drug (IND)-enabling work for APVO451, Aptevo's novel trispecific antibody-like immunotherapy candidate for solid tumors.

Aptevo believes that obtaining this competitive award, reviewed by subject matter experts and awarded based on

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Tue, 30 Jun 2026 08:05:00 -0400

Aptevo believes that obtaining this competitive award, reviewed by subject matter experts and awarded based on

Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: NIOWAVE, INC.

Mon, 22 Jun 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26671860.html

Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: NIOWAVE, INC.

Mon, 22 Jun 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26671860.html

Form 3 Aptevo Therapeutics Inc. For: May 25 Filed by: NIOWAVE, INC.

Mon, 22 Jun 2026 11:45:00 -0400

si-local-file:///var/storage/secattach/20260622/26671730.html

Form 3 Aptevo Therapeutics Inc. For: May 25 Filed by: NIOWAVE, INC.

Mon, 22 Jun 2026 11:45:00 -0400

si-local-file:///var/storage/secattach/20260622/26671730.html

Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo

Thu, 28 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260528/26569367.html

Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo

Thu, 28 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260528/26569367.html

Aptevo Therapeutics names Mary Janatpour as chief scientific officer

Thu, 28 May 2026 08:05:08 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) appointed Mary J. Janatpour as Senior Vice President and Chief Scientific Officer, the clinical-stage biotechnology company announced.

Janatpour brings more than 25 years of oncology research and development experience across biotechnology and pharmaceutical organizations. She will lead Aptevo's research and preclinical development efforts and advance the company's pipeline of multispecific therapeutics based on its ADAPTIR and ADAPTIR-FLEX platform technologies.

The appointment comes as Aptevo focuses clinically on mipletamig while advancing a preclinical strategy that includes a radiopharmaceutical therapeutic collaboration with Niowave and an expanding multispecific oncology pipeline.

"Mary joins Aptevo at a pivotal moment as we continue to

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

Thu, 28 May 2026 08:05:00 -0400

Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy

SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™ platform technologies, today announced the appointment of Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer.

Dr. Janatpour brings more than 25 years of oncology research and development leadership across biotechnology and pharmaceutical organizations, with deep expertise spanning target discovery, translational science, and pipeline strategy.

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

Thu, 28 May 2026 08:05:00 -0400

Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy

Form 8-K Aptevo Therapeutics Inc. For: May 25

Wed, 27 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260527/26557776.html

Form 8-K Aptevo Therapeutics Inc. For: May 25

Wed, 27 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260527/26557776.html

Aptevo and Niowave form partnership for cancer drug development

Wed, 27 May 2026 08:05:49 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. announced a strategic collaboration to develop up to three radiopharmaceutical oncology programs. The 50/50 partnership combines Aptevo's multispecific antibody platforms with Niowave's radioisotope production capabilities.

Niowave made an equity investment in Aptevo at closing, acquiring an initial 7.9% ownership position. The investment structure includes warrants that could allow Niowave to increase its stake to 19.99% through future purchases at a premium to the initial price.

Under the agreement, Aptevo will contribute assets from its ADAPTIR and ADAPTIR-FLEX platforms, starting with targeting assets directed against Nectin-4, a protein expressed on cancer cell surfaces. Niowave will

Aptevo and Niowave form partnership for cancer drug development

Wed, 27 May 2026 08:05:49 -0400

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Wed, 27 May 2026 08:05:00 -0400

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology

SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, and Niowave, Inc., a leader in radioisotope production and supply with established partnerships across the radiopharmaceutical ecosystem, today announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.

Niowave made an at-the-market equity investment in Aptevo at